Which anticoagulant is safest for patients with morbid obesity?
Patients on warfarin or NOACs have a similar number of events, finds US study
Non-vitamin K oral anticoagulants (NOACs) and warfarin appear to be similarly safe in morbidly obese patients with atrial fibrillation (AF) and venous thromboembolism (VTE), according to new US findings.
“In patients with a BMI of at least 40 there didn’t seem to be more thrombotic events or bleeding events in those who were on direct oral anti-Xa inhibitors compared to the ones on [warfarin],” said lead author Dr Margarita Kushnir of Montefiore Medical Center, in New York City.
